CBD has the potential to harm you, and harm can occur even before you know it. CBD can affect the way other medications you're taking work, which could cause serious side effects. However, some side effects of CBD have been described, but mainly in vitro or in animal studies. They include alterations in cell viability, reduced fertilization capacity, and inhibition of hepatic drug metabolism and drug transporters (for example, in these studies, a sufficient number of subjects must be enrolled to discuss long-term safety aspects and possible interactions of CBD with other substances).
Your message was successfully sent to your colleague. What is CBD? Cannabidiol is a chemical substance found in cannabis plants. It's a cannabinoid, but CBD isn't psychoactive and doesn't produce a euphoric high. CBD appears to have some sedative effects at high doses.
Undoubtedly, this case report has problems. The authors did not specify the nature of the patient's interstitial nephritis or why he was being treated with tacrolimus. This is disconcerting because tacrolimus can cause interstitial nephritis and kidney failure. Unfortunately, the document does not contain enough clinical information to resolve these problems.
Should PE be concerned about adverse effects and drug interactions in a patient who takes a CBD gummy bear every day? My opinion is that “worry” is too strong a word. There is no doubt that doctors should be aware of the potential adverse effects of taking high doses of CBD, but also that a patient is not likely to ingest even close to a worrying dose unless they are taking Epidiolex. The efficacy of topical cannabidiol oil in the symptomatic relief of peripheral neuropathy of the lower extremities. A phase 1, open-label, parallel group, single-dose trial on the pharmacokinetics and safety of cannabidiol (CBD) in subjects with mild to severe hepatic impairment.
Pathways that mediate the effects of cannabidiol in reducing breast cancer cell proliferation, invasion and metastasis. Cannabidiol in vivo reduces beta-amyloid-induced neuroinflammation by suppressing the expression of IL-1beta and iNOS. Evaluation of the antinociceptive efficacy of cannabidiol alone or in combination with morphine using the formalin test in male and female mice. Over the past decade, extensive research has demonstrated that cannabidiol (CBD) has the potential to treat a variety of disorders.
Effects of cannabidiol and diazepam on behavioral and cardiovascular responses induced by contextual conditioned fear in rats. Effects of cannabidiol supplementation on skeletal muscle regeneration after intensive resistance training. Palmitoylethanolamide and cannabidiol prevent inflammation-induced hyperpermeability of the human intestine in vitro and in vivo: a randomized, placebo-controlled, double-blind trial. Vasoprotective endothelial effects of chronic cannabidiol treatment and its influence on the endocannabinoid system in rats with primary and secondary hypertension.
Cannabidiol reduces anxiety induced by pretending to speak in public in patients with social phobia who have not received previous treatment. Cognitive functioning after long-term use of cannabidiol in adults with treatment-resistant epilepsy. Antitumor activity of plant cannabinoids with emphasis on the effect of cannabidiol on human breast cancer. Cannabidiol induces programmed cell death in breast cancer cells by coordinating the conversation between apoptosis and autophagy.
Neuroprotective effect of cannabidiol, a non-psychoactive component of Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells. .